CompletedNCT03448146Updated Feb 28, 2018

A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction

A Phase 3 interventional study of Para-Toluenesulfonamide in Nsclc, sponsored by PTS International Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 83 Years. Per ClinicalTrials.gov, last updated 2018-02-28.

Sponsored by PTS International Inc. · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 90
Allocation: Not applicable
Ages: 18 Years to 83 Years
Sex: All

Study summary

This trial was to evaluate the efficacy of intratumoral PTS injection in alleviating airway obstruction and dyspnea by improving the percentage of lumen patency of patients with central air way NSCLC tumor severe obstruction.

Read the detailed description

Local intratumoral injection of para toluenesulfonamide (PTS) via bronchoscopy could alleviate airway obstruction for patients with central air way NSCLC tumor severe obstruction, which contributed to the shrinkage of target tumor lesions in a short period, with an objective response rate of 66% and an improvement rate of luminal tumor obstruction of 70% in the end-of-treatment period.
Patient's pulmonary function, atelectasis and quality of life were improved significantly after treatment, indicating that PTS treatment cuold relieve the symptoms of air way obstruction and provide clinical benefits to the patients.
Adverse events were mainly blood streaked sputum, injection site haemorrhage, cough, pyrexia and oropharyngeal pain, without reporting of potential risks. Common study drug related adverse events included injection site haemorrhage, cough, and blood streaked sputum and oropharyngeal pain. The multi-center clinical study conducted strictly in accordance with Standard Operation Procedures for the Use of a Standard Bronchoscope in Local Intratumoral PTS Injection showed that PTS had good safety and tolerability and that the procedural risks of intratumoral PTS injection via bronchoscopy could be controlled.
The advantages of PTS for treatment of airway lung cancer obstruction included significant efficacy, good safety, large applicable population; relatively simple equipment conditions and operation, thus it could be spread easily. PTS is also expected to be used in the treatment of central lung cancer with acute airway obstruction in combination with other treatments (such as stent implantation), which provides a new drug treatment to patients with airway lung cancer obstruction. PTS can complement with other treatments, which is expected to improve the treatment efficacy significantly.

Conditions studied

Nsclc

Browse trials for

Carcinoma, Non-Small-Cell Lung 6,475

Who can participate

Ages eligible: 18 Years to 83 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Male or female inpatients, aged 18 to 83 years old.
Patients with central air way non-small cell lung cancer (NSCLC) severe obstruction; definition of severe airway obstruction: ≥1/2 trachea is obstructed by tumor; and/or block ≥2/3 of primary bronchi, right and middle bronchi. And the longest diameter of the lesion > 0.5 cm.
Pathologically confirmed lung cancer.
Patients with tracheal tumor lesions suitable for local intratumoral injection via fibro-bronchoscopy.
At least one measurable lesion that could be evaluated by imaging examination (bronchoscopy, CT, MRI or X-ray etc.) according to the Response Evaluation Criteria in Solid Tumors.
Blood platelet count ≥ 100,000/mm3.
Subjects who were able to understand and comply with the trial protocol and give written consent.

Exclusion criteria

Exclusion Criteria:

Brain metastases.
History of cardiovascular diseases, including congestive heart failure > New York Heart Association (NYHA) Grade II. Patients with unstable angina pectoris (angina pectoris symptoms at rest), recent angina pectoris (occurred in the recent 3 months) or with myocardial infarction in recent 6 months must be excluded.
Severe infections or dysbolism.
Poor hepatic functional reserve or severe hepatocirrhosis, with abnormal blood coagulation indicators.
Poor general conditions or cachexia.
The target lesion had been treated with radiotherapy within 6 months.
Pregnant or breast-feeding woman.
Known hypersensitivity to PTS or related compounds.
Lung cancer lesions not suitable for local treatment.
Any other reason deemed reasonable by the investigator.

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 90 participants (actual)

Study arms

Experimental
Para-Toluenesulfonamide
1. .The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor. 2. . In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient. The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient.
Drug: Para-Toluenesulfonamide

Interventions

DrugPara-Toluenesulfonamide
Also known as: PTS

What researchers measure

Primary outcomes

Objective response rate
The objective response rate of target lesions in patients with central air way NSCLC tumor severe obstruction after PTS treatment were evaluated based on measurement results of CT and bronchoscopy.
Time frame: 30 days after the last treatment
Improvement rate of luminal obstructions
The improvement rate of luminal obstructions in patients with central air way NSCLC tumor severe obstruction after PTS treatment were evaluated based on measurement results of CT and bronchoscopy.
Time frame: 30 days after the last treatment

Secondary outcomes

Change in FVC
Changes in Forced Vital Capacity (FVC)
Time frame: 30 days after the last treatment
Change in FEV1/FVC
Changes in Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC)
Time frame: 30 days after the last treatment
Change in BDI score
Changes in Baseline Dyspnea Index (BDI) score. The BDI provides a multidimensional measurement of dyspnea based on 3 domains: functional impairment, magnitude of task and magnitude of effort that evoke dyspnea in activities of daily living, in symptomatic individuals. Rated in five grades from 0 to 4 for each domain. Ranging from 0 to 12. The lower the score, the worse the severity of dyspnea.
Time frame: 30 days after the last treatment
Change in pleural effusion
Changes in pleural effusion
Time frame: 30 days after the last treatment
Change in ECOG performance status
Changes in Eastern Cooperative Oncology Group (ECOG) performance status
Time frame: 30 days after the last treatment
Change in QOL score
Changes in Quality of Life (QOL) score. Quality of life (QOL) was evaluated based on the subject's answers in Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) questionnaire, version 4. Symptoms of lung cancer were evaluated according to the completed Lung Cancer Subscale (LCS). The FACT-LCS, version 4 is a patient completed questionnaire consisting 36 items that assesses health related quality of life (HRQL) in lung cancer patients. The FACT-LCS, version 4 consists of the 27-item FACT-G assessing generic HRQL concerns and 9-item Lung Cancer Subscale assessing disease-specific issues. Instrument scoring yields a range from 0 to 144 with higher scores representing better patient status.
Time frame: 30 days after the last treatment
Duration of response (DOR) of target lesion
Duration of response (DOR) of target lesion
Time frame: 30 days after the last treatment

Study locations

1 site

The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China

References and documents

Publications

Li SY, Li Q, Guan WJ, Huang J, Yang HP, Wu GM, Jin FG, Hu CP, Chen LA, Xu GL, Liu SZ, Wu CG, Han BH, Xiang Y, Zhao JP, Wang J, Zhou X, Li HP, Zhong NS. Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial. Lung Cancer. 2016 Aug;98:43-50. doi: 10.1016/j.lungcan.2016.05.012. Epub 2016 May 17. PubMed 27393505 ↗

Registry details

Key details

Study ID: NCT03448146
Lead sponsor: PTS International Inc.
Responsible party: Sponsor
First posted: Feb 27, 2018
Start date: Aug 2009
Primary completion: Dec 2011
Completion: Dec 2011
Last update: Feb 28, 2018

Study contacts

Nan Shan Zhong

principal investigator · The First Affiliated Hospital of Guangzhou Medical University

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma, Non-Small-Cell Lung→

Other studies from this sponsor

PTS International Inc.

A Study of PTS for Patients With Solid TumorsWithdrawnNCT03448211Phase 1

Start the discussion